Sangamo Wins OK For Cheaper $35M Ch. 11 Loan
Biotechnology company Sangamo Therapeutics received interim approval Thursday to tap into a new, $35 million Chapter 11 financing package with a lower interest rate....To view the full article, register now.
Already a subscriber? Click here to view full article